[1] JOSEPHSON C D,GLYNN S A,KLEINMAN S H,et al.A multidisciplinary think tank:the top 10 clinical trial opportunities in transfusion medicine from the National Heart,Lung,and Blood Institute-sponsored 2009 state-of-the-science symposium[J].Transfusion,2011,51(4):828-841.
[2] PELLEGRIN S,SEVERN C E,TOYE A M.Towards manufactured red blood cells for the treatment of inherited anemia[J].Haematologica,2021,106(9):2304-2311.
[3] KUPZIG S,PARSONS S F,CURNOW E,et al.Superior survival of ex vivo cultured human reticulocytes following transfusion into mice[J].Haematologica,2017,102(3):476-483.
[4] GIARRATANA M C,ROUARD H,DUMONT A,et al.Proof of principle for transfusion of in vitro-generated red blood cells[J].Blood,2011,118(19):5071-5079.
[5] ZHANG Y,WANG C,WANG L,et al.Large-scale ex vivo generation of human red blood cells from cord blood CD34+ cells[J].Stem Cells Transl Med,2017,6(8):1698-1709.
[6] NHS Blood And Transplant.First ever clinical trial of laboratory grown red blood cells being transfused into another person[EB/OL].(2022-11-07)[2023-8-22].https://www.nhsbt.nhs.uk/news/first-ever-clinical-trial-of-laboratory-grown-red-blood-cells-being-transfused-into-another-person/.
[7] VAN DEN AKKER E,SATCHWELL T J,PELLEGRIN S,et al.The majority of the in vitro erythroid expansion potential resides in CD34 (-) cells,outweighing the contribution of CD34+ cells and significantly increasing the erythroblast yield from peripheral blood samples[J].Haematologica,2010,95(9):1594-1598.
[8] SEVERN C E,MACEDO H,EAGLE M J,et al.Polyuretha ne scaffolds seeded with CD34+ cells maintain early stem cells whilst also facilitating prolonged egress of haematopoietic progenitors[J].Sci Rep,2016,6:32149.
[9] ZHOU X L,YUAN J,LIU J F,et al.Loading trehalose into red blood cells by electroporation and its application in freeze-drying[J].Cryo Letters,2010,31(2):147-156.
[10] COHN C S,STUBBS J,SCHWARTZ J,et al.A comparison of adverse reaction rates for PAS C versus plasma platelet units[J].Transfusion,2014,54(8):1927-1934.
[11] BAILEY S L,FANG L Y,FITZPATRICK L,et al.In vitro and in vivo effects of short-term cold storage of platelets in PAS-C[J].Haematologica,2022,107(4):988-990.
[12] STRAMER S L,HOLLINGER F B,KATZ L M,et al.Emerging infectious disease agents and their potential threat to transfusion safety[J].Transfusion,2009,49(Suppl 2):1S-29S.
[13] ESTCOURT L J,MALOUF R,HOPEWELL S,et al.Pathogen-reduced platelets for the prevention of bleeding[J].Cochrane Database Syst Rev,2017,7(7):CD009072.
[14] GARBAN F,GUYARD A,LABUSSIÈRE H,et al.Comparison of the hemostatic efficacy of pathogen-reduced platelets vs untreated platelets in patients with thrombocytopenia and malignant hematologic diseases:a randomized clinical trial[J].JAMA Oncol,2018,4(4):468-475.
[15] SUGIMOTO N,KANDA J Y,NAKAMURA S,et al.iPLAT1:the first-in-human clinical trial of iPSC-derived platelets as a phase 1 autologous transfusion study[J].Blood,2022,140(22):2398-2402.
[16] MACLENNAN S,HARDING K,LLEWELYN C,et al.A randomized noninferiority crossover trial of corrected count increments and bleeding in thrombocytopenic hematology patients receiving 2- to 5- versus 6- or 7-day-stored platelets[J].Transfusion,2015,55(8):1856-1865;quiz 1855.
[17] GAMMON R R,HEBERT J,MIN K,et al.Cold stored platelets - Increasing understanding and acceptance[J].Transfus Apher Sci,2023,62(3):103639.
[18] MURPHY S,GARDNER F H.Effect of storage temperature on maintenance of platelet viability—deleterious effect of refrigerated storage[J].N Engl J Med,1969,280(20):1094-1098.
[19] REDDOCH K M,PIDCOKE H F,MONTGOMERY R K,et al.Hemostatic function of apheresis platelets stored at 4℃ and 22℃[J].Shock,2014,41 Suppl 1(0 1):54-61.
[20] STUBBS J R,TRAN S A,EMERY R L,et al.Cold platelets for trauma-associated bleeding:regulatory approval,accreditation approval,and practice implementation-just the tip of the iceberg[J].Transfusion,2017,57(12):2836-2844.
[21] JOHNSON L,VEKARIYA S,WOOD B,et al.Refrigeration of apheresis platelets in platelet additive solution (PAS-E) supports in vitro platelet quality to maximize the shelf-life[J].Transfusion,2021,61(Suppl 1):S58-S67.
[22] STRANDENES G,SIVERTSEN J,BJERKVIG C K,et al.A pilot trial of platelets stored cold versus at room temperature for complex cardiothoracic surgery[J].Anesthesiology,2020,133(6):1173-1183.
[23] BIOBRIDGE GLOBAL.FDA grants South Texas Blood&Tissue Center first license for new process that triples shelf life of critically needed platelets[EB/OL].(2020-02-28)[2023-8-22].https://www.globenewswire.com/news-release/2020/02/28/1992715/0/en/FDA-grants-South-Texas-Blood-Tissue-Center-first-license-for-new-process-that-triples-shelf-life-of-critically-needed-platelets.html.
[24] ClinicalTrials.gov.Study Record | Beta ClinicalTrials.gov [EB/OL].(2023-08-16)[2023-8-22].https://www.clinicaltrials.gov/study/NCT04834414.
[25] COHN C S,WILLIAMS S.Cryopreserved platelets:the thaw begins… (Article,p.2794)[J].Transfusion,2019,59
(9):2759-2762.
[26] CELLPHIRE.Cellphire Therapeutics Clinical Trials - Cryopreserved Platelets[EB/OL].(2021-09-30)[2013-8-22].https://www.cellphire.com/clinical-trials-cryopreserved-platelets.
[27] HOROWITZ B,LAZO A,GROSSBERG H,et al.Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma[J].Vox Sang,1998,74(Suppl 1):203-206.
[28] HELLSTERN P,SOLHEIM B G.The use of solvent/detergent treatment in pathogen reduction of plasma[J].Transfus Med Hemother,2011,38(1):65-70.
[29] SAADAH N H,SCHIPPERUS M R,WIERSUM-OSSELTON J C,et al.Transition from fresh frozen plasma to solvent/detergent plasma in the Netherlands:comparing clinical use and transfusion reaction risks[J].Haematologica,2020,105(4):1158-1165.
[30] MARIETTA M,FRANCHINI M,BINDI M L,et al.Is solvent/detergent plasma better than standard fresh-frozen plasma? A systematic review and an expert consensus document[J].Blood Transfus,2016,14(4):277-286.
[31] COHN C S.The AABB Technical Manual[M].20th ed.2020.
[32] LU T,NAHATA P,JOHNSON A,et al.Comparison of bacterial risk in cryo AHF and pathogen reduced cryoprecipitated fibrinogen complex[J].Pathogens,2022,11(7):744.
[33] HANOVER J.INTERCEPT Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex[EB/OL].(2020-11-30)[2023-8-22].https://www.businesswire.com/news/home/20201130005353/en/Cerus-Corporation-Announces-FDA-Approval-for-INTERCEPT-Blood-System-for-Cryoprecipitation.
[34] FDA.November 24, 2020 Approval Order-INTERCEPT Blood System for Plasma[Z].2020.
[35] DE VRIES R R P,FABER J C,STRENGERS P F W,et al.Haemovigilance:an effective tool for improving transfusion practice[J].Vox Sang,2011,100(1):60-67.
[36] GAMMON R R.standards for blood banks and transfusion method[M].32nd ed.Bethesda MD: 2020.
[37] CAP A P,BECKETT A,BENOV A,et al.Whole blood transfusion[J].Mil Med,2018,183(suppl_2):44-51.
[38] CONDRON M,SCANLAN M,SCHREIBER M.Massive transfusion of low-titer cold-stored O-positive whole blood in a civilian trauma setting[J].Transfusion,2019,59(3):927-930.
[39] SEHEULT J N,ANTO V,ALARCON L H,et al.Clinical outcomes among low-titer group O whole blood recipients compared to recipients of conventional components in civilian trauma resuscitation[J].Transfusion,2018,58(8):1838-1845. |
